Korea's Fair Trade Commission Looking Into Allegations That MNCs Offered Kickbacks To Block New Generic Entrants
This article was originally published in PharmAsia News
Executive Summary
SEOUL - The South Korean government's fair trade watchdog - the Fair Trade Commission - is investigating reports of "reverse payments" or kickbacks offered to local Korean generic drug makers by multinational pharmaceutical companies to keep generics off the market after patents expire on an original drug
You may also be interested in...
Korea's Health Ministry To Unveil Steeper Price Cuts After Patent Loss; Generics Could Be The Big Loser
SEOUL - Korea's Ministry of Health and Welfare confirmed that it is preparing a new pricing system to further cut prices of both innovative products and generics. The plan could deal a blow to Korea's generic-dependent pharmas by eventually eliminating price differences of generics and off-patent brands under Korea's national health insurance
Brand-Generic "Pay-For-Delay" Settlements Jump 63% In FY 2010
As a proportion of total settlements reported to FTC, however, the ones involving compensation to the generic firm remained the same.
Korean Government Launches Strongest-ever Drive To Root Out Rebates
SEOUL - In the strongest ever all-out government crackdown on rebates between hospital doctors and pharmaceutical companies, the Korean government established a joint task force at a Seoul Prosecution Office that it hopes will add teeth to better enforce anti-rebate laws implemented last November